Susan Galbraith, AstraZeneca EVP, oncology R&D
October 26, 2022 07:33 AM EDTUpdated 09:39 AM
R&D

As­traZeneca spot­lights pos­i­tive PhII, PhI­II read­out for a pair of next-gen breast can­cer drugs

Amber Tong

Two decades af­ter the FDA first ap­proved ful­ves­trant to treat a type of breast can­cer, As­traZeneca says it has gar­nered da­ta that could ush­er in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times